|
Phenyltoloxamine Citrate
» Phenyltoloxamine Citrate contains not less than 99.0 percent and not more than 101.0 percent of C17H21NO·C6H8O7, calculated on the dried basis.
Packaging and storage
Preserve in well-closed containers. Store at room temperature.
USP Reference standards
USP Phenyltoloxamine Citrate RS. USP Phenyltoloxamine Related Compound A RS.
Identification,
Infrared Absorption
pH
Loss on drying
Residue on ignition
Heavy metals, Method I
Related compounds
Resolution solution
In a separatory funnel dissolve about 10 mg each of USP Phenyltoloxamine Citrate RS and USP Phenyltoloxamine Related Compound A RS, accurately weighed, in 50 mL of water. Add 5 mL of ammonium hydroxide, and extract with three 10-mL portions of methylene chloride. Combine the extracts, dry the solution over anhydrous sodium sulfate, and gently evaporate to dryness. Dissolve the residue in 20 mL of methylene chloride.
Test solution
In a separatory funnel dissolve about 400 mg of Phenyltoloxamine Citrate, accurately weighed, in 50 mL of water. Proceed as directed for Resolution solution, beginning with Add 5 mL of ammonium hydroxide.
Chromatographic system (see Chromatography
Procedure
Inject a volume (about 1 µL) of the Test solution into the chromatograph, record the chromatograms, and measure the peak responses. Calculate the percentage of each impurity in the portion of Phenyltoloxamine Citrate taken by the formula:
100(ri / rs)
in which ri is the peak response of each impurity; and rs is the sum of the responses of all the peaks, excluding the solvent peaks: not more than 0.2% of phenyltoloxamine related compound A; not more than 0.1% of any other individual impurity; and not more than 1.0% of total impurities is found.
Assay
Dissolve about 0.5 g of Phenyltoloxamine Citrate, accurately weighed, in 80 mL of glacial acetic acid, and titrate with 0.1 N perchloric acid VS, determining the endpoint potentiometrically. Perform a blank determination, and make any necessary correction (see Titrimetry
Auxiliary Information
Please check for your question in the FAQs before contacting USP.
USP32NF27 Page 3291
Pharmacopeial Forum: Volume No. 30(4) Page 1291
|